Nuvalent News and Activities

Nuvalent is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Nuvalent is a company listed under the stock ticker NUVL (US).

Acquisition, funding and merger involving Nuvalent.

• GSK has announced the acquisition of Nuvalent  (posted on June 9 2026).

View the org chart displaying its 51 main executives

Most searched biographies at Nuvalent

• James Porter, Chief Executive Officer
• Anna Protopapas, Chairman of the Board
• Grant Bogle, Director

Popular executive movements at Nuvalent

• Matthew Metivier, Senior Vice President and Head of Human Resources, has left the company  (posted on June 9 2026).
• Jason Agostinelli, who was Associate Director, Accounting, is promoted to Director, Accounting Operations  (posted on June 9 2026).
• Jimmy Yung, Senior Manager, Financial Planning and Analysis, has left the company  (posted on March 25 2026).

Click here to view some more movements at Nuvalent

Create your alert
to follow the executive moves at Nuvalent.

Nuvalent has 2,424 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• The new name of EG 427 is Cyllene Therapeutics. (posted on July 10 2026).
• Opthea will change its company name to Ceryvyn Therapeutics on Jul 9, 2026. (posted on July 9 2026).
• Tissium has just announced a $60 Million fundraising (posted on July 8 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Nuvalent

• Nuvalent Investors -
• Nuvalent Investors -
• News | Nuvalent

Social media about Nuvalent

• Nuvalent on Wikipedia, Google News & Yahoo Finance
• Nuvalent on LinkedIn, X (Twitter) & YouTube